Industry

HIMALAYA Phase III trial subgroup analysis showed that IMFINZI plus tremelimumab improved overall survival vs. sorafenib in patients with unresectable liver cancer regardless of baseline liver functional reserve TOPAZ-1 Phase III trial subgroup analysis showed the addition of IMFINZI to standard-of-care chemotherapy improved overall survival benefit in patients with advanced biliary tract cancer regardless of … [Read more…]

TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will begin his employment on August 1, 2022, and will be based out of Teva’s U.S. headquarters in Parsippany, NJ. Dr. Hughes … [Read more…]

Hologic Taking Action with ‘Hey, U!’ Campaign to Educate Women in Conjunction with Fibroid Awareness Month MARLBOROUGH, Mass.–(BUSINESS WIRE)–#Fibroidawarenessmonth–A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options. Today, in conjunction with … [Read more…]

ST. HELIER, Jersey–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss the company’s financial results for the three and six months ended June 30, 2022, … [Read more…]

SUWON, South Korea–(BUSINESS WIRE)–#AMD—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this Phase … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Hospital-Acquired Infection Diagnostics Market Size, Share & Industry Trends Analysis Report By Product, By Infection Type, By Application, By Test Type, By End User, By Regional Outlook and Forecast, 2022 – 2028” report has been added to ResearchAndMarkets.com’s offering. The Global Hospital-Acquired Infection Diagnostics Market size is expected to reach $5.6 billion … [Read more…]

Ameet Mallik, Chief Executive Officer of ADC Therapeutics, also joins the Board LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appointed as the Company’s Chief Executive Officer in May 2022, will join the Board. … [Read more…]

MILAN–(BUSINESS WIRE)–Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it is extending its Senior Management team through the appointment of Filippo Moriggia to the newly created position of Vice President … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Drug Injection Devices to 2028” report has been added to ResearchAndMarkets.com’s offering. The correlation between chronic conditions and the benefits of patient self-administration continues to influence therapeutic product decisions, managed care initiatives and regulatory actions. Drug injection device designs are increasingly being based on the results of human engineering inputs and patient preference … [Read more…]

Sana places fifth in the medium category for Austin Business Journal’s annual contest that recognizes businesses with unparalleled company cultures Sana’s culture is rooted in empathy, fulfillment and happiness, bringing one’s whole self to work, a commitment to work-life balance and superlative benefits The company continues to grow and scale, with plans to add 30 … [Read more…]